<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678574</url>
  </required_header>
  <id_info>
    <org_study_id>9803010098</org_study_id>
    <nct_id>NCT00678574</nct_id>
  </id_info>
  <brief_title>The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder</brief_title>
  <official_title>The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study proposed is to investigate the role of neurosteroids and GABA in the&#xD;
      pathophysiology and treatment of premenstrual dysphoric disorder (PMDD) by 1) measuring&#xD;
      cortical gama-aminobutyric acid levels (GABA levels) using nuclear magnetic resonance&#xD;
      spectroscopy (MRS) during the follicular and mid-luteal phases of the menstrual cycle pre and&#xD;
      post treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Prozac®,&#xD;
      Sarafem®), and 2) correlating cerebrospinal fluid (CSF) and plasma GABA and neurosteroid&#xD;
      levels with cortical GABA levels at these same time points. Neurosteroids to be measured&#xD;
      include allopregnanolone, pregnenolone, and pregnenolone sulfate. Findings from women with&#xD;
      PMDD will be compared to those of healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cortical Gama-aminobutyric Acid Levels (GABA Levels) Pre and Post SSRI Treatment</measure>
    <time_frame>2-3 months post-treatment w/ fluoxetine.</time_frame>
    <description>GABA levels would be assessed during the follicular and mid-luteal phases of the menstrual cycle pre and post treatment with the SSRI.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Premenstrual Dysphoric Disorder</condition>
  <condition>Premenstrual Syndrome</condition>
  <arm_group>
    <arm_group_label>Premenstrual Dysphoric Disorder (PMDD) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PMDD group received fluoxetine 20 mg daily by mouth for 2-3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluoxetine</intervention_name>
    <description>Fluoxetine 20 mg daily by mouth for 2-3 months.</description>
    <arm_group_label>Premenstrual Dysphoric Disorder (PMDD) group</arm_group_label>
    <other_name>Prozac</other_name>
    <other_name>Sarafem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 - 45 years old and able to give voluntary written informed consent.&#xD;
&#xD;
          -  Willing to complete a daily log of mood symptoms for 7 consecutive menstrual cycles:&#xD;
             two menstrual cycles during the Screening Phase (Phase 1), one menstrual cycle during&#xD;
             the Testing Phase (Phase 2), and four menstrual cycles during the Medication Treatment&#xD;
             Phase and Post-Treatment Phase (Phase 3). All subjects who successfully complete&#xD;
             Phases 1 and 2, and the Medication Treatment Phase, will be invited to participate in&#xD;
             Phase 3 approximately three months later. Phase 3 will involve repeating all&#xD;
             procedures conducted in Phase 2, including the daily log of mood symptoms.&#xD;
&#xD;
          -  Meet DSM-IV criteria for premenstrual dysphoric disorder, confirmed by the Daily&#xD;
             Record of Severity of Problems (DRSP; Endicott &amp; Harrison) for 2 consecutive menstrual&#xD;
             cycles (Phase 1). The DRSP is a self-rated symptom checklist, which requires&#xD;
             individuals to rate their symptoms of PMDD according to the DSM-IV research criteria&#xD;
             scale on a scale from 1 (symptom not present) to 6 (symptom extreme). During the last&#xD;
             7 days of the menstrual cycle compared to days 5-11, patients must have a 30% increase&#xD;
             in their average (over 2 menstrual cycles) score for 5 of these 10 symptoms. Symptoms&#xD;
             must be &quot;not present&quot; or &quot;minimal&quot; during the postmenstrual week.&#xD;
&#xD;
          -  Average 19-item Hamilton Depression Rating Scale (HAM-D) scores &lt; 5 during the&#xD;
             follicular phase and &gt; 16 during the luteal phase.&#xD;
&#xD;
          -  Have regular menstrual cycles 28 to 32 days in length. Each of the screening cycles&#xD;
             must be ovulatory as confirmed by plasma progesterone levels of &gt;5 ng/ml during the&#xD;
             luteal phase.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any other comorbid DSM-IV Axis I disorder.&#xD;
&#xD;
          -  Meeting DSM-IV criteria for psychoactive substance (excluding nicotine) dependence&#xD;
             within the preceding 4 months.&#xD;
&#xD;
          -  A history of serious medical or neurological illness, including (but not limited to)&#xD;
             major cardiovascular disease, severe hypertension, intracranial mass lesions, seizure&#xD;
             disorder, severe hepatic or renal disease, unstable endocrine or metabolic disease,&#xD;
             and unstable hematologic disease.&#xD;
&#xD;
          -  Use of anticonvulsant or benzodiazepines within the last month.&#xD;
&#xD;
          -  Use of psychotropic medication in last week (except as stated above).&#xD;
&#xD;
          -  Use of steroid contraceptives within the previous 4 months, including birth control&#xD;
             pill, birth control patch, birth control ring, and Depo-Provera®. Subjects will be&#xD;
             asked to use abstinence or the barrier method (condoms) as forms of contraception in&#xD;
             this study.&#xD;
&#xD;
          -  Alcohol consumption greater than 7 drinks/week.&#xD;
&#xD;
          -  Current pregnancy.&#xD;
&#xD;
          -  Metallic implants.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia N Epperson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania School of Medicine Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>May 13, 2008</study_first_submitted>
  <study_first_submitted_qc>May 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2008</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>June 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2017</results_first_posted>
  <last_update_submitted>July 25, 2018</last_update_submitted>
  <last_update_submitted_qc>July 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hormones</keyword>
  <keyword>menses</keyword>
  <keyword>PMS</keyword>
  <keyword>PMDD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premenstrual Syndrome</mesh_term>
    <mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>45 subjects were recruited at an outpatient practice at Yale University, CT.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PMDD</title>
          <description>Participants who qualified as having PMDD received fluoxetine 20 mg daily by mouth for 2-3 months</description>
        </group>
        <group group_id="P2">
          <title>Healthy Controls</title>
          <description>Participants who did not qualify for a diagnosis of PMDD and did not receive drug treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PMDD Group</title>
          <description>Fluoxetine 20 mg daily by mouth for 2-3 months to the PMDD group</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls</title>
          <description>No intervention was provided to the healthy control group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cortical Gama-aminobutyric Acid Levels (GABA Levels) Pre and Post SSRI Treatment</title>
        <description>GABA levels would be assessed during the follicular and mid-luteal phases of the menstrual cycle pre and post treatment with the SSRI.</description>
        <time_frame>2-3 months post-treatment w/ fluoxetine.</time_frame>
        <population>This study was conducted at Yale several years ago. Our group at UPenn only has basic information about this study. This includes the number of participants, which was 18, and that no adverse events occurred. The contact person who initially entered this study protocol information is no longer at the University of Pennsylvania.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine</title>
            <description>Fluoxetine 20 mg daily by mouth for 2-3 months in PMDD group</description>
          </group>
          <group group_id="O2">
            <title>No Intervention</title>
            <description>No intervention was provided in the healthy control group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cortical Gama-aminobutyric Acid Levels (GABA Levels) Pre and Post SSRI Treatment</title>
          <description>GABA levels would be assessed during the follicular and mid-luteal phases of the menstrual cycle pre and post treatment with the SSRI.</description>
          <population>This study was conducted at Yale several years ago. Our group at UPenn only has basic information about this study. This includes the number of participants, which was 18, and that no adverse events occurred. The contact person who initially entered this study protocol information is no longer at the University of Pennsylvania.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected throughout the course of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluoxetine</title>
          <description>Fluoxetine 20 mg daily by mouth for 2-3 months in PMDD group</description>
        </group>
        <group group_id="E2">
          <title>No Treatment</title>
          <description>Healthy controls received no treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data from this study has not yet been analyzed nor peer reviewed. As much information as possible was entered into the results section of this trial, however information is missing as it pertains to specific measurements collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cynthia Neill Epperson, M.D.</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-573-8871</phone>
      <email>cepp@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

